Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the securities of Allergy Therapeutics plc. On August 17, 2023, Panmure Gordon purchased 2,194 0.1p ordinary shares at a price of 0.0242 per unit. No sales were made. The disclosure does not include any cash-settled derivative transactions or stock-settled derivative transactions. There are no indemnity or option arrangements, agreements, or understandings related to relevant securities. The disclosure was made in accordance with Rule 8 of the Takeover Code.